Cardium Therapeutics has completed the second tranche of its previously announced registered direct offering consisting of an additional 1,656 shares of Series A convertible preferred stock for gross proceeds of approximately $1.7 million, bringing the total gross proceeds of the offering to approximately $4.0 million.
For a detailed description of the terms of the securities purchase agreement as well as the rights, privileges, and preferences of the Series A Convertible Preferred Stock, view CXM’s current report on Form 8-K here: http://dtg.fm/45Ml.
CXM is an asset-based health sciences and regenerative medicine company engaged in the acquisition and strategic development of products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization.
For more information, visit www.cardiumthx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
